Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

44.98
+1.683.88%
Volume:1.47M
Turnover:65.74M
Market Cap:7.47B
PE:-12.93
High:45.36
Open:43.21
Low:43.12
Close:43.30
52wk High:86.74
52wk Low:42.63
Shares:166.18M
Float Shares:161.92M
Volume Ratio:2.02
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:17.00
PE(LYR):-18.89

Loading ...

Ionis Completes Enrollment in Pivotal Cohort of the Phase 3 Reveal Study Evaluating Obudanersen in Angelman Syndrome

THOMSON REUTERS
·
Jul 06

Ionis EVP, Chief Clinical Development Officer Eugene Schneider Disposes of 26,000 Shares for $2.11 Million

Reuters
·
Jul 01

Ionis EVP Research Eric Swayze Sells 10,602 Shares for $839,082.60

Reuters
·
Jun 27

Movement Alert|Ionis Pharmaceuticals Rises 5.32% in Regular Trading, Zilganersen Global Commercialization Accelerates via Recordati Licensing Deal

Market Focus
·
Jun 26

Ionis Pharmaceuticals Inc : Piper Sandler Raises Target Price to $110 from $100

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 25

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jun 25

Ionis Licenses Alexander Disease Drug Zilganersen to Recordati Outside US for $30 Million Upfront

Reuters
·
Jun 25

Ionis Pharmaceuticals - Plans Independent U.S. Launch of Zilganersen; FDA Pdufa Date Set for September 22

THOMSON REUTERS
·
Jun 25

Ionis Announces License Agreement with Recordati for Zilganersen in Alexander Disease (axd) in All Countries Outside the U.S.

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals - to Retain U.S. Commercial Rights and Lead Global Development of Zilganersen

THOMSON REUTERS
·
Jun 25

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals - Tryngolza Available in 50 Mg or 80 Mg Dose, Self-administered Monthly

THOMSON REUTERS
·
Jun 25

Tryngolza® (olezarsen) Approved by the FDA as the First and Only Treatment to Reduce Triglycerides and the Risk of Acute Pancreatitis in Patients with Severe Hypertriglyceridemia (shtg)

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals - Tryngolza to be Available in U.S. for Shtg in July

THOMSON REUTERS
·
Jun 25

FDA: Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia

THOMSON REUTERS
·
Jun 25

Ionis' Tryngolza Receives FDA Approval to Treat Acute Pancreatitis in Severe Hypertriglyceridemia Patients

MT Newswires Live
·
Jun 25

FDA announces approval of Ionis’ Tryngolza for hypertriglyceridemia

TIPRANKS
·
Jun 24

How Olezarsen’s Longer-Term Hepatic Data and High Retention Could Shape Ionis Pharmaceuticals (IONS) Investors

Simply Wall St.
·
Jun 20